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Teaser This review presents a systematic analysis on methods employed for assessing
acceptability of oral medicines in children and older adults, to provide insights and
recommendations regarding the design of reliable instruments in future studies.
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Acceptability of medicinal products in children and older populations is
pivotal in ensuring adherence and therapeutic outcomes. This review
systematically identifies studies reporting on formulation aspects of oral
medications that affect their acceptability in these patient groups.
Particular emphasis is placed on the evaluation of the methodologies
employed in the studies. Sixty-eight studies were included for analysis,
with 51 (75%) in children and 17 (25%) in older populations. The studies
evaluated a range of oral formulations; however, the methodologies used
differ considerably in participants’ characteristics, study settings, tools,
acceptability definitions and criteria. It is evident that there is a lack of
standardisation in study design as well as the assessment methods used in
assessing acceptability of medicines in children and older populations.
Introduction
Global regulatory initiatives are fostering the development of patient-centric pharmaceutical
products that accommodate the needs of all users, including children, older adults and their
caregivers. The lack of suitable formulations for children and older patients is increasingly
acknowledged by the regulatory and scientific communities given the prevalence of unlicensed
and off-label medicine use, undocumented modifications of dosage forms, patient-reported
administration difficulties and rates of non-adherence [1–10]. In addition to being burdensome
to patients and their caregivers, these practices can be detrimental to the safety and efficacy of
medicines [11–14]. As an example, tablets are often subdivided (split) into smaller segments to aid
swallowing or to acquire a more suitable dose; however, this might be inappropriate for certain
drug products. For example, subdivision of a tablet could lead to unequal segments with
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The applied search terms
Keywords Synonyms
Populations Elderly, older adults, aging, ageing, geriatric, paediatric,
pediatric, children, infant, newborn, adolescent, teens,
youth, teenagers
Route Oral
Formulations Formulation, dosage form
Assessments Satisfaction, acceptance, preference, approval, acceptability,
swallow, palatability
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Wnonuniform drug doses [15–18]. When a whole tablet has been
coated with an enteric or modified release coating, breaking the
tablet could compromise the functionality of the coating and
hence alter bioavailability.
The European Medicines Agency (EMA) and Food and Drug
Administration (FDA) have adopted legislations to promote the
timely development and authorisation of medicines for use in
children (between birth and 16 years in the USA and up to 18 years
in Europe) [19–22]. To support this, the EMA released a reflection
paper in 2005 broadly outlining factors to be considered in the
development of formulations for children [23]. As knowledge,
opinion and experience in the field developed, the agency issued
another guideline in 2014 further capturing considerations in the
development of age-appropriate paediatric medicines [24]. At
present, a draft reflection paper on the pharmaceutical develop-
ment of medicines for use in the older people (defined as adults
from 65 years of age) has also been released for public consultation
[25]. Although not exhaustive, these documents emphasise the
importance of recognising the distinct needs of children and older
adults when designing drug products.
Particular emphasis is placed on establishing ‘patient
acceptability’ of pharmaceutical products, defined as: ‘the ability
and willingness of a patient to use and its caregiver to administer
the medicine as intended’ [24,25]. Ensuring that formulations are
suitably designed and acceptable to end-users reduces the risks
that medicine quality could be compromised, supports patient
adherence and consequently leads to safer and effective use of
medicines [9,10]. Acceptability is influenced by factors related to
pharmaceutical product design (such as route of administration,
dosage form design, dosing frequency and features of administra-
tion and product packaging), as well as the characteristics of end-
users [26,27]. A patient’s ability to use formulations as intended
can vary, and is often dependent on several physiological, physical
and psychological factors. Physiological functions and cognitive
and motor skills inherently develop and mature from birth to
adulthood. At the other end of the spectrum, aging is characterised
by the decline and deterioration in the functional capacity of
organs, with elderly patients often presenting with physical and
cognitive impairments, multiple comorbidities, polypharmacy
and frailty [28]. As such, development of medicines suitable for
use in children and older patients raises unique and related chal-
lenges around drug disposition, safety of excipients and limita-
tions with practical usability of dosage forms. In both populations,
caregivers often play an important part in facilitating the admin-
istration or management of medicines – in children before they
can be given responsibility for their own medication intake and in
older people if they become unable to manage their medicines.
Collectively, these aspects increase the complexity of patient-
centric pharmaceutical product design.
The lack of empirical evidence on suitability and end-user
opinions of pharmaceutical formulations across both populations
is well documented [29–31]. Consequently, the current EMA
guidelines advocate that patient acceptability is evaluated as an
integral part of pharmaceutical and clinical development [24], and
over the product lifecycle [25]. Ideally, this pivotal data should be
sought from patients and caregivers themselves as a fundamental
outcome of well-designed clinical studies with the proposed med-
icine. Alternative sources could provide indications of adequatepatient acceptability, such as human factor studies with patients or
healthy volunteers, using existing clinical trial data, or market
experiences and literature reports [8,32–34]. However, knowledge
regarding suitable methodologies for testing acceptability is sparse
and fragmented, and a harmonised approach between industry
and regulators is lacking [35]. Recent reviews have presented
literature evidence of acceptability of pharmaceutical formula-
tions in children and older patients [29–31]. This review aims to
identify studies reporting on formulation aspects of oral medica-
tions that have been shown to influence their acceptability in
paediatric and older populations, with a specific emphasis on the
evaluation of the methodological approaches to provide insights
and recommendations to the design of reliable instruments in
future studies.
Methods
Search strategy
Indexed publications were identified by searching three electronic
databases: Pubmed, Scopus and Embase, with coverage from the
start date to May 2017 for all sources. The search strategy com-
bined Boolean operators (‘AND’) using any of the search terms
shown in Table 1. In addition, a manual search of references
within publications included from the electronic search was con-
ducted to complement the electronic search. Literature collections
from expert members of the European Paediatric Formulation
Initiative (EuPFI) were also reviewed.
Selection criteria
Four reviewers (F.L., S.R.R., F.L.L. and F.R.) independently con-
ducted initial screens of identified abstracts and titles. Abstracts
were excluded if they were not in the English language, did not
report original data (e.g., review papers) or were duplicates. Articles
were included in the review if the age of the study population was
in the ranges between 0 and 18 years and >60 years. Although the
WHO has used the chronological age of 65 years as the definition
of ‘an older or elderly person’ [36], historically 60 years of age has
been applied as the cut-off age for ‘older population’ or ‘geriatrics’
and was therefore adopted in the inclusion criteria of this review.
Where a study had a population with a mixture of age ranges, the
study was included if (i) the mean/median age was between 0 and
18 years or >60 years, (ii) separate results were presented for age
groups of 0–18 years old or >60 years old, or (iii) >50% of parti-
cipants were between 0 and 18 years or >60 years old.
Studies were included if patient acceptability of an oral formu-
lation was evaluated, as defined by the EMA as ‘an overall ability of
the patient and caregiver (defined as ‘user’) to use a medicinalwww.drugdiscoverytoday.com 831
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measures of swallowability (the capacity to ingest an oral formu-
lation upon administration into the oral cavity) [25] and key
organoleptic properties such as shape, size, colour, texture and
palatability. Because this review focuses on the pharmaceutical
formulation itself, studies evaluating aspects such as packaging,
medicine administration devices and the impact of dosing fre-
quency were not included. Studies that solely focused on taste
assessment or taste comparisons of different formulations were
also excluded because this has been reviewed elsewhere [37,38].
However, studies were included if taste assessment was part of the
overall acceptability evaluation of the formulation. Evaluation of
medicine adherence (or compliance) applies different definitions
and assessment methods to acceptability [39] and studies solely
investigating these outcomes were also excluded. Disagreements
about the eligibility of studies were resolved by consensus, includ-
ing, where necessary, with the input of additional reviewers.
Data extraction
Data were extracted by each reviewer into structured summary
tables and cross-checked for accuracy. Discrepancies were resolved
by consensus, including, where necessary, with the input of addi-
tional reviewers. Key details extracted for each study included
formulation characteristics (e.g., dosage form type, size, shape
and drug content), participant age and health condition, reporting
persons (i.e., self-report or report by caregivers or observers),
sample size, study setting (country location and data collection
setting), design and acceptability assessment and primary out-
comes.
Results
The electronic search identified 2590 records potentially eligible
for inclusion (Fig. 1). Following a manual screening of titles,
abstracts and full-texts, 44 publications were eligible for inclusion.
An additional 24 papers were included after manual screening of
references within eligible publications and through studies iden-
tified by the expert panel. Therefore, a total of 68 publications were
included for analysis. The characteristics of the included studies
are summarised in Table 2. A total of 51 (75%) publications were
paediatric-population-based studies and 17 (25%) were based on
the older population. The earliest study identified was published in
1987, whereas 42 articles (62% of the combined total) were pub-
lished in the past decade from 2007 to 2017, showing increasing
research intensity in this area. Sixty studies (88% of the combined
total) were conducted in European and Northern American coun-
tries.
Tables 3 and 4 summarise the methodology and outcomes of
each eligible study with regards to the acceptability assessment.
Thirty studies (44%) assessed the acceptability of one single type of
oral dosage form, for example tablets, capsules or suspensions
(Table 3), whereas the remaining studies (n = 38, 56%) evaluated
or compared more than one type of dosage form, for example the
acceptability or preference of tablet versus oral suspension (Table
4). For paediatric-based studies (n = 51), the individual who pro-
vided the responses to the acceptability assessment included chil-
dren (n = 21, 41% of the total paediatric studies), caregivers
including parents and carers (n = 19, 37% of the total paediatric
studies), children and caregivers (n = 10, 20% of the total paediat-832 www.drugdiscoverytoday.comric studies) and observers or investigators (n = 1, 2% of total
paediatric studies). Thirty-five percent (24/68) of the studies eval-
uated the acceptability of medicines already being prescribed to
the patients, whereas in the rest of the studies (65%) patients
received medicines for the purpose of testing their acceptability.
Further details on the methodology directly related to the
acceptability assessment were extracted and are listed in Table
5. Questionnaires (n = 41, 60%) were the most commonly applied
method in assessing acceptability of formulations, followed by
observations (n = 16, 24%) that mostly related to observing the
ability of the participant to swallow oral formulations. A variety of
terms were used to describe or measure the acceptability (Table 5);
‘acceptability’ was the most commonly used term (n = 17, 25%)
followed by ‘preference’ (n = 13, 19%). More than one-third of the
studies (n = 26, 38%) lacked a clear definition on acceptability or
other synonymous terms used. It is noteworthy that no studies
included in the analysis provided standardised criteria for accept-
ability assessment, for example the ‘acceptability rate’ or the
minimum % rate that would deem the formulation to be consid-
ered acceptable to patients.
Discussion
Study types and settings
In assessing formulation aspects of oral medications that influence
their acceptability in the paediatric and older populations, this
review examined 68 studies with 51 paediatric- and 17 older-
population-based studies. Evident from examining these studies
is the lack of standardisation in study design and the assessment
methods used. Table 6 summarises study design considerations for
dosage form acceptability assessments in children and older
adults. All aspects of study design differ considerably in the
reviewed studies. The types of the studies include clinical trials
evaluating efficacy and tolerability of treatments, standalone
investigations into acceptability of medicines such as post-mar-
keting surveys and swallowability evaluation of solid dosage forms
[3,8,34,57–72] (Table 2). The settings where the studies took place
ranged from hospitals and specialised clinics to community-based
environments (e.g., home, school, community centres) (Table 2).
It is acknowledged that patient acceptability is influenced not only
by formulation attributes but also characteristics of the patient (e.
g., disease type and stage). In this regard, acceptability studies
performed in the targeted patient population during prospective
studies such as clinical trials and observational studies in post-
marketing surveys could provide a more representative insight
into the true acceptability of the formulation compared with
studies conducted in healthy volunteers. However, it should be
noted there could potentially be a selection bias in clinical trials
because only patients who are willing to participate are included.
In addition, in studies nested to clinical trials, it can be difficult to
deconvolute the effect of the dosage form design from the effect of
the efficacy or safety balance of the medicine (e.g., appearance of
adverse events). Although clinical trials are often conducted in
standardised conditions, the translation of the outcomes to
patients taking the medicines at home or at school might not
be straight forward. Studies conducted in healthy subjects using
placebo formulations can provide fundamental understanding of
the acceptability of different dosage form designs. Equally, it
might not be possible to generalise acceptability findings of a
Drug Discovery Today Volume 23, Number 4  February 2018 REVIEWS
Records identified through database
searching
Pubmed (n = 980)
Scopus (n = 1302)
Embase (n = 308)
Total results produced (n = 2590)
Abstracts retrieved and evaluated
n = 150
Publications included
(n = 44)
Exclusion of duplicates
(n = 2463)
Full-text articles excluded
(n = 10):
Population age range not
eligible (n = 3)
Taste assessment (n = 4)
Non-oral formulation (n = 1)
Conference abstract (n = 2)
Total publications included
(n = 68)
Manual screening of references (n = 11)
Manual screening of papers sent from
expert panel (n = 13)
Full-text article accessed and assessed
n = 54
Abstracts excluded (n = 96):
No acceptability test
conducted (n = 53)
Taste assessment (n = 23)
Population age range not
eligible (healthy/normal adult
volunteers) (n = 7)
Review article (n = 8)
Non-oral route (n = 3)
Adherence study (n = 2)
Drug Discovery Today 
FIGURE 1
Literature search results on studies reporting acceptability of oral medicines in paediatric and older patients.
Re
vi
ew
s
 K
EY
N
O
TE
R
EV
IE
Wformulation, for example swallowability of a certain dosage form
in a certain patient group, to other settings and patient groups
because it can be influenced by the environment and the char-
acteristics of the patient. For example, a substantial discrepancy in
the prevalence of dysphagia symptoms between older patients in
nursing homes (68%) and community-dwelling older adults has
been found (11%) [73,74].
Participant characteristics
The participant characteristics varied in terms of age, disease
status, developmental stages and/or age-related impairments in
the reviewed studies. Age is often used in the classification of the
paediatric and older populations. Although guidance is available
to define paediatric subgroups according to age (ICH E11), this wasnot followed by the majority of paediatric-based studies with a
wide variety of age ranges used, for example 0–26 years in one
study [75] and 6 months to 14 years in another [76]. Although
arbitrary age was suggested to be used to divide subgroups of the
older population, numerical age alone scarcely correlates with
physiological functions of the older individual or outcomes of
interventions. Classification of the frailty status of older patients
was proposed to be a more accurate reflection of physiological
activities and abilities [77]. Healthy volunteers and patients with a
range of diseases were recruited into these studies (Tables 2–4).
Disease conditions, especially the presence of multiple morbidities
in the older patient, might affect the experience and acceptance of
patients to take their medicines. Similar effects might be seen from
patients’ past experiences in taking medicines and the nature ofwww.drugdiscoverytoday.com 833
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TABLE 2
Study characteristics across the paediatric and older adult
populations: data are number (%) of studies
Study characteristics Paediatric-
population-
based studies
(n = 51)
Older-adult-
population-
based studies
(n = 17)
Year of publication
2017–2007 34 (66) 8 (47)
2006–1997 14 (27) 4 (24)
1996–1987 3 (6) 5 (29)
Journal field
Nutrition 3 (6) –
Medical 42 (82) 11 (65)
Pharmacy 6 (12) 6 (35)
Location of study
Europe 28 (55) 10 (59)
North America 18 (35) 4 (24)
Asia 2 (4) 3 (18)
Africa 3 (6) –
Type of study
Clinical trials 12 (24) 3 (18)
Swallowability evaluation 18 (35) 6 (35)
Other 21 (41) 8 (47)
Study setting
Specialist clinics/centres 9 (18) 4 (24)
Community baseda 16 (31) 2 (12)
Hospital based 20 (39) 8 (47)
Multi-settings 5 (10) 1 (6)
Not specified 1 (2) 2 (12)
Population size
0–50 17 (33) 5 (29)
51–99 7 (14) 2 (12)
100–199 10 (20) 5 (29)
200–299 3 (6) –
300–399 5 (10) 1 (6)
400–499 2 (4) –
500+ 7 (14) 4 (24)
Health conditions of participants
Healthy volunteers 9 (18) 4 (24)
Taking medicines – reason unknown 2 (4) 1 (6)
In hospital – reason unknown 8 (15) –
With disease conditionsb 32 (63) 12 (71)
a Include: homes, general practitioners, schools, pharmacies and preventive health
centres.
b Disease conditions include acute childhood diarrhoea, after surgery, allergies,
Alzheimer’s disease, asthma, cystic fibrosis, dysphagia, eligible for typhoid vaccination,
epilepsy, HIV, hyperactivity disorder, hypercholesterolaemia, hypertension, infections
requiring prescription of antibiotics, iron deficiency, malnutrition, nephrotic syndrome,
oesophageal obstruction, osteoporosis, Parkinson’s disease, phenylketonuria, primary
nocturnal enuresis, respiratory tract infections, sickle cell disease, type 2 diabetes and
undergoing adentonsillectomy.
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macy in the older patient). For instance, differences were reported
in the preference of tablet colours between older patients taking
small and large numbers (>10) of tablets each day [78]. To add to
the complexity, variations in children’s development and age-
related impairments in the older population (e.g., visual, cognitive
and motoric functions) could also affect patient handling and
taking their medicines.834 www.drugdiscoverytoday.comStudy methods and tools
The selection of the applied study methods and tools reflected the
purpose of the studies. For example, assessing the swallowability of
tablets and capsules was often done by direct observation or
instrumental examination (e.g., videoendoscopy), whereas gener-
al acceptability of a formulation or medicine was conducted by
interviews and questionnaires accompanied by facial and visual
analogue scales (Tables 3 and 4). Age-appropriate facial scales have
been developed for taste assessment in paediatrics and can be
adapted for acceptability studies [37], although careful consider-
ation must be given to the choice of scales and response options to
avoid bias [79]. Two studies have used multiple endpoints to report
the acceptability; for example, using the combination of children
and parent reporting on acceptability and direct observation on
the outcome of the intake [41,80]. These combinations of end-
points might minimise the bias of using one method for reporting
the acceptability. In the majority of the studies (65%), patients
received medicines or placebo formulations for the purposes of
assessing their acceptability and a smaller proportion of studies
(35%) evaluated acceptability of medicines that have already been
prescribed to the patients. Although using patients’ own medi-
cines gives a real-world judgement on the use of the medicines, it is
necessary to conduct perspective studies such as randomised trials
to compare the acceptability of newer types of medicines or
formulations to conventional ones.
With regards to methodological details, differences were ob-
served between studies in terms of number of participants, study
duration, number of administration attempts and who was re-
sponsible for answering the questions. In paediatric-based studies,
feedback on acceptability or otherwise of the formulations was
given almost equally by the children and their parents or care-
givers (Tables 3 and 4). However, it is interesting to note that in
certain studies caregiver or parental response was used for children
older than 12 years (up to 26 years old) [34,75,81]. In most of the
older-population-based studies, acceptability was evaluated by the
patients themselves, with the exceptions of caregivers’ satisfaction
for medicines used in the treatment of Alzheimer’s and Parkinson’s
diseases. This was probably because of the disease-related decline
in patients’ capacity in participating in the studies [82,83]. How-
ever, the acceptability of the patient might differ from that
reported by caregivers.
Clarification is required regarding circumstances under which
the caregiver’s (parent’s or partner’s) response should be used
instead of the patient’s in the paediatric and older populations.
FDA guidance on patient-reported outcome (PRO) measures could
provide some valid insight into this question [22]. This guidance
highlights the challenge of PROs in children and in patients who
have cognitive impairment or are unable to communicate. For
these populations, especially patients who cannot respond for
themselves, the FDA encourages observer reports that include only
those events or behaviours that can be observed, and discourages
proxy-reported outcome measures. As an extension of this guid-
ance, in 2013 an International Society for Pharmacoeconomics
and Outcomes Research (ISPOR) taskforce proposed good practices
for paediatric PRO research, which is conducted to inform regula-
tory decision-making and support claims made in medical product
labelling [84]. These recommendations propose that there is no
clear evidence of child-report reliability and validity in children
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TABLE 3
Methods and acceptability results in studies that assessed a single dosage forma
Formulation type Drug content Participant
age range
Persons who
gave the
acceptability
response
Acceptability
assessment method
Acceptability synonym and
definition
Summary of acceptability
results
Refs
Tablets (7 mm,
cylinder)
Placebo 6–12 years Children Observation and six-
point visual scale
‘Ability in swallowing the
tablet’, not defined; and ‘ease
of swallowing’, not defined
91% of children were able to
swallow a tablet; 89.5%
subjects performed the task
without difficulty and 10.5%
exhibited a little difficulty
[70]
Tablets – 11–20 years Children Semi-structured
qualitative interview
‘Capability to swallow
medicines’, not defined
Over one-third (n = 32) of
adolescents expressed
difficulty in taking oral
medicines mostly owing to
their taste and size
[3]
Tablets (7 mm
round)
Ketoprofen 1–9 years Parents Questionnaire ‘Problems in administering
tablets’, not defined
14% parents reported
problems in administering
the tablets to their children
which related to difficulty in
swallowing the tablets
[94]
Tablets (film coated,
5–8 mm, round)
Levamisole 2–18 years Children Observation ‘Ability to swallow the
medicine’, not defined
Children swallowed 1–7
tablets every other day for
several months and no
problem with swallowing
tablets was reported
[95]
Minitablets (3 mm,
uncoated)
Placebo 2–6 years
(divided
into four
age groups)
Children Observation ‘Success in swallowing’,
defined as the tablet being
swallowed whole; chewing,
spitting out and refusal were
defined as ‘nonswallowed’
The proportion of children
who successfully swallowed
the mini-tablet was 45–55%,
76% and 87% for 2–3 years, 4
years and 5 years old,
respectively
[71]
Mini-tablets (2 mm
and 3 mm)
Placebo 2–3 years Children Observation ‘Ability to swallow’, defined as
complete deglutition
including ‘smooth
swallowing’, ‘swallowing with
a choking reflex or cough’, or
‘biting or chewing followed
by swallowing’
83% of children were able to
swallow five or ten mini-
tablets of the tested sizes with
the aid of fruit jelly on a
spoon. However, only 57% of
all children were capable of
swallowing the tablets
without chewing
[69]
Capsules containing
microtablets
Pancrelipase MT 6–30
months
Parents Questionnaire with
four-point palatability
scale (0 being poor and
3 being excellent)
‘Palatability’, defined as ease
of swallowing
The median palatability score
was 2.6 during the
randomisation period
[51]
Gelatin capsules
from ‘sprinkle’ size,
through 4,3,2, and 1,
to 1000 IU capsule
sizes
Placebo 3–13 years Children Observation ‘Success in swallowing pills’;
not defined
17 children learned to
swallow the pills through
training and 11 failed to learn
to swallow the pills
[62]
Gelatin capsules of
increasing sizes
Placebo 4–21 years Children Observation ‘Success in pill swallowing’,
not defined
95.7% children were
successful in swallowing the
pills through training
[64]
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TABLE 3 (Continued )
Formulation type Drug content Participant
age range
Persons who
gave the
acceptability
response
Acceptability
assessment method
Acceptability synonym and
definition
Summary of acceptability
results
Refs
Gelatin capsules (#5
to #00 in size)
Placebo 3.5–17.5
years
Children Observation ‘Success in swallowing’,
defined as pill ingestion and
in clean mouth after
swallowing
Training was performed on
four disabled children and
had varied degree of success
in improving capacity in
swallowing capsules
[57]
Tablets and capsules
of various sizes
Placebo 4–9 years Children Observation ‘Success in pill swallowing’,
not defined
Seven out of eight children
improved pill swallowing by
training
[59]
Tablets of various
shapes and capsules
Placebo 67–95
(mean 81)
years
Patients Video-endoscopy ‘Penetration Aspiration Scale
(PAS)’
Compared with
administration of milk alone,
swallowing the tablets and
capsules significantly
increased the PAS values in
patients with stroke-induced
dysphagia
[8]
Enteric coated
capsules
Typhoid vaccine 4–6, 7–9,
10–12 years
Children Observation ‘Success in swallowing the
medicine’, defined as ability to
swallow the capsule without
breaking them
The success rates for
swallowing the capsules were
84.4%, 94.2% and 100% for
the age groups of 4–6 years,
7–9 years and 10–12 years
[96]
Capsules Radiolabelled placebo
gelatin capsule, sized
#1, #0 and #00
70–81 years Radio
scintigraphy
Radio-scintigraphy ‘Oesophageal clearance’,
defined as the radioactivity in
the oesophagus returned to
10% of peak value
Capsule retention in the
oesophagus can occur in
older patients even when the
dosage form was ingested
with a large amount of fluid
(three out of nine elderly
subjects)
[58]
ODTsb Placebo and
ondansetron
5–11 years Children Observation and
questionnaire
‘Acceptability’, observational
acceptance defined as not
reject or spit out;
questionnaire assessed taste,
sensation and willingness to
take the medication in the
future
100% observational
acceptance; however, a
significantly larger number of
the subjects in the
ondansetron group found the
tablet not tasting ‘good’
compared with the control
group; 13% in the
ondansetron group stated
that they would not be willing
to take the medication in the
future
[41]
ODTs Amlodipine 58.3% aged
65 years
Patients Interview ‘Palatability’, defined as
easiness to ingest
99.6% found the formulation
‘easy to ingest’
[54]
ODTs Voglibose 64.4 11.2
years
Patients Questionnaire assessed
using comparison to
conventional tablets as
‘easier’, ‘no difference’ or
‘more difficult’
‘Convenience of taking the
medicine’, not defined
53.1% reported that taking
the ODT was easier than
taking conventional tablet
[56]
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TABLE 3 (Continued )
Formulation type Drug content Participant
age range
Persons who
gave the
acceptability
response
Acceptability
assessment method
Acceptability synonym and
definition
Summary of acceptability
results
Refs
Dispersible tablets Zinc 0–60
months
Caretakers Interview Problems in administrating
the tablets
Eight caretakers (6.5%)
reported problems with
administering the tablet to
their child
[97]
Dispersible tablets Zinc 3–59
months
Caretakers Questionnaire, assessed
using comparison to
other medicines as
‘better’, ‘same’ or ‘worse’
‘Acceptability’, measured on
the basis of child’s behaviour
when given the medication
93.1% of caretakers reported
that the tablets were equally
or more acceptable to their
children than other medicines
[98]
Dispersible tablets Fixed-dose
combinations (FDC) of
antimalaria drugs,
artemether-
lumefantrine (AL) and
dihydroartemisinin-
piperaquine (DP)
6–59
months
Caregivers Questionnaire ‘Ease of use’ and
‘acceptability’, not defined
Caregivers reported that the
two dispersible FDC tablets to
be simple to use (82%, 67%),
having good palatability
(72%, 56%) and preferred the
dispersible tablet over syrup
(76.8%, 62.3%) for both
products
[48]
Suspensions Antibiotics Median
range 18–
22 months
Parents Telephone interview
using three- or five-
point scales
‘Acceptance’, defined using
willingness to swallow and
occurrence of vomiting;
‘satisfaction’, defined as
‘extremely satisfied’ and
‘satisfied’ on the scale
Percentage satisfaction was
reported as 89, 81, 74 and
67% for four suspensions,
respectively
[99]
Suspension Mercaptopurine 3–12 years Children and
parents (for
children below
the age of 6)
Questionnaire using
five-point facial hedonic
scale
‘Acceptability’, not defined 77% children rated the taste
of the formulation between
‘okay’ to ‘good’; 82% reported
that it was ‘easy to take all the
time’
[100]
Suspensions
reconstituted from
tablets
Roxithromycin 2–8 years Investigator Observation using a six-
point scale
‘Acceptability’, defined as
child smiling or without
making a face during taking
the medicine
The investigator reported the
acceptability as good, fairly
good or acceptable in 70.5%
of children
[47]
Oral drops Vitamin K Infants Midwives Questionnaire ‘Acceptability’, not defined 56% of midwives reported the
use of the oral drop as ‘quite
acceptable’ or ‘completely
acceptable’ with 33%
undecided and 11% reporting
it as ‘not very acceptable’
[101]
Oral formulations in
general
Hydroxyurea 5–17 years Parents Questionnaire ‘Ability to swallow medicines’,
not defined
98% of children could
swallow liquid medications;
75.5% and 72.5% could
swallow tablets and capsules,
respectively
[34]
w
w
w
.d
ru
g
d
isco
veryto
d
ay.co
m
 
8
3
7
Reviews KEYNOTE REVIEW
R
EV
IEW
S
 
D
ru
g
 D
isco
very
 To
d
ay
Vo
lu
m
e
 23,
 N
u
m
b
er
 4
Feb
ru
ary
 2018
TABLE 3 (Continued )
Formulation type Drug content Participant
age range
Persons who
gave the
acceptability
response
Acceptability
assessment method
Acceptability synonym and
definition
Summary of acceptability
results
Refs
Oral formulations in
general
Antibiotics 0–12 years Parents Questionnaire No specific terms were used.
The use and the problems
related to the use of the
formulations were measured
11% of the parents had
difficulty in administering the
medicines to their child.
Fewer administration-related
problems were associated to
tablets and capsules than to
suspensions and soluble
tablets
[102]
Oral formulations in
general
All medicines included 0–26 years Parents Questionnaire ‘Acceptance’, defined as
history of medication
rejection, frequency of use
and ability to ‘easily’ swallow
tablets and capsules
33.5% and 39.2% of children/
adolescents had rejected
liquid and pills, respectively,
at least once
[75]
Tablets or capsules
using in situ coating
(MedCoatJ) as an
aid
Patients’ own
medications
2–17 years
(mean 9
years)
Children or
parents
Questionnaire ‘Tolerance’, defined as the
facilitation of drug treatment,
swallowing ability and drug
palatability
The ability to swallow tablets
or capsules improved in 68 of
78 children after in situ
coating
[72]
Oral formulations
(including liquids,
tablets and capsules)
using Pill Glide as an
aid
Patients’ own
medications
6–17 years Children Self-reporting diaries,
using six-point numeric
or facial hedonic scale
(0 indicating not
difficult to 5 most
difficult)
Medicine Taking Difficulty
Score (MTDS) indicating
‘difficulty/ease of swallowing
medications’
Pill Glide decreased 0.93
overall MTDS for swallowing
solid medications
[66]
Tic tac (candy) using
Pill Glide as an aid
Candy 9–17 years Children Observation ‘Success in pill swallowing’,
not defined
Seven of the 11 adolescents
were successful in swallowing
the pill using Pill Glide as an
aid
[63]
a Single dosage form assessed: only one type of dosage form, e.g., tablet or capsule, was investigated. Drug-containing and placebo formulations can be assessed; however, they are presented as the same dosage form.
b ODT: orally disintegrating tablets.
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TABLE 4
Methods and acceptability results in studies that compared two or more dosage forms
Small (0.287  0.710 inches)
vs large (0.360  0.760
inches) tablets
Dietary
supplements
Above 50 (mean age
68) years
Patients Questionnaire using VASb (100mm,
higher scores mean more
preferable)
‘Preference’ ranked based on
eight aesthetic characteristics
and overall preference
Significantly more patients
preferred smaller than larger
tablets
[60]
Two different tablet
formulations (Ketovite and
RSM)
Micronutrient 1–16 years (mean 10
years)
Children
and family
Questionnaire using a Likert scale
from 1 (liked) to 7 (disliked)
Opinion about the medication,
with respect to appearance,
smell, texture, ease of
administration, taste, size and
acceptability
Children generally swallowed
Ketovite tablets because of their
smaller size; the RSM was
chewed by most children owing
to larger size. 53% of families
were in favour of changing
Ketovite to the RSM, especially if
its size were reduced
[42]
Tablets vs film-coated
dispersible tablets
Acyclovir 71–94 (mean 82)
years
Patients Questionnaire ‘Ease of swallowing’ Standard tablets and film-
coated dispersible tablets were
swallowed whole with 200 ml
water. 50% of subject did not
have any preference between
the formulations. Of those who
had expressed a preference,
79% preferred the film-coated
dispersible tablet
[103]
Tablets (fixed dose
combination) vs effervescent
calcium tablets plus vitamin
drops
Calcium and
vitamin D
70–95 years Patients Questionnaire ‘Acceptability’, defined as overall
satisfaction, taste and
presentation
A significantly higher proportion
of patients were satisfied with
their treatments with the fixed
dose combination tablet
formulation; no significant
differences were found for other
acceptability parameters such as
taste and presentation between
the two formulations
[50]
Tablets (1.3 g) vs other
commonly used forms
(powder, drink and capsules)
Protein substitute Median 15 years,
ranging 8–25 years
Patients Questionnaire using VAS (100 mm,
higher scores mean more
acceptable)
‘Acceptability’, defined as
palatability, smell, ease of
swallowing and gastrointestinal
intolerance
70% patients preferred tablets
over their previously used
protein substitute formulations
[45]
Tablets vs oral lyophilisate
formulation (MELT)
Desmopressin 5–15 years Patients Questionnaire using VAS (100 mm
with 0means very easy and 100 very
difficult to use)
‘Preference’ and ‘ease to use’
which is not defined
56% preferred MELT vs 44%
preferred tablets; VAS scores
were 22.2 28.3 mm and 22.6
27.0 mm for MELT and tablets,
respectively
[44]
Tablets vs powder Cholestyramine 10–18 years Patients Questionnaires with six-point Likert
scales
‘Acceptability’, defined as
preferences at the end of the
study
82% participants preferred
tablets and 16% preferred
powder
[46]
Tablets (4 mm) vs powder vs
suspension vs syrup
Placebo 1–4 years Parents Questionnaire using VAS (0–10 cm;
0 means very unpleasant and 10 not
at all unpleasant)
‘Acceptability’, defined using
VAS score by parents’
observation and result of the
intake (whether or not
swallowed); and ‘preference’
defined as the single most
preferred formulation by child
and parent
The mean VAS scores were 9.01,
8.20, 7.90 and 8.19 for the tablet,
powder, suspension and syrup,
respectively; children and
parents preferred the tablet and
syrup over the suspension and
the suspension over the powder
[80]
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Film-coated tablets
(5.7  11.6 mm) vs gelatin
capsule (#3, 5.8  15.9 mm)
Placebo Mean age 66 years – Gamma scintigraphy ‘Oesophageal transit’ Prolonged oesophageal transit
was observed for the capsules
compared to the film-coated
tablets
[104]
Tablets vs ODTsa Carbidopa-
levodopa
71.8 8.3 years, with
Pakinson’s disease
Patients Global Preference Questionnaire ‘Preference’ 45% of patients preferred ODTs
compared to 20% preferred
conventional tablets
[105]
Tablets vs ODTs Placebo 64.5 11.8 years – Videoendoscopy ‘Swallowing performance’,
assessed by number of
swallows, total time of swallow,
use of liquid to assist
swallowing, residue in the
hypopharynx and airway
compromise
Significantly more numbers of
swallows and longer duration of
swallowing were required to
swallow tablets compared to
ODTs in patients with dysphagia
[61]
Halved scored tablets vs
syrup
Antiretroviral
drugs
3 months to 17 years Parents Questionnaire ‘Acceptability’, defined as
preference, difficulties and
associated problems
The proportion of caregivers
and children who preferred
tablets over syrup was 97% and
59%, respectively. All children
who preferred syrup were under
4 years old. 64% of children took
the tablets dissolved or crushed
and administered with a small
amount of liquid
[81]
Minitablets (2 mm,
uncoated) vs syrup
Placebo 0.5–6 years (divided
into six age groups)
Children Observation ‘Acceptance’, defined as
swallowing and chewing with
subsequent swallowing for the
minitablet, and not defined for
syrup
Overall acceptance of the mini-
tablet was higher or equal to
that of the syrup in all age
groups
[106]
Uncoated and coated 2 mm
minitablets vs syrup
Placebo 6 months to 1 year,
1–2 years, 2–3 years,
3–4 years, 4–5 years
and 5–6 years
Children Observation ‘Acceptability’, defined as
swallowed and chewed before
swallowing for the mini-tablets
and everything swallowed and
small trickle or left over for the
syrup
78.4–100% acceptability for the
uncoated minitablets; 84.3–
100% acceptability for the
coated minitablets and 64.7–
90.2% acceptability for the
syrup; two incidents of
coughing were observed for the
coated minitablets
[68]
Mini-tablets (uncoated,
2 mm) vs syrup
Placebo Median 4 days (range
2–28 days)
Children Observation ‘Acceptability’ defined as
complete or partial swallowing;
‘swallowability’, defined as
complete swallowing
100% acceptability was
obtained for the mini-tablet and
syrup formulations.
Swallowability was significantly
higher for mini-tablets (82.2%)
than syrup (72.2%). No serious
adverse events (coughing or
coking) were observed for both
formulations
[67]
Tablets, pellets (minitablets)
vs syrup
Lopinavir 3 months to 13 years
(divided into three
age groups)
Caregivers Questionnaire ‘Acceptability’, reported as
caregivers’ preference
For children below 12 months
and 4 years old, 44% and 36%
preferred pellets over syrup
after 48 weeks’ usage; for older
children (4–13 years), only 13%
preferred pellets to tablets after
48 weeks
[107]
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Chewable tablets vs sachet Calcium and
vitamin D3
supplement
Mean age 66 years Patients Questionnaire using a 0–10 rating
scale for assessing acceptability,
higher score indicating higher
acceptance
‘Preference’ and ‘acceptability’
which is defined using five
questions relating to the
convenience of use of the
medicines
67% patients preferred
chewable tablets compared to
19% preferred sachet; chewable
tablets received significantly
higher acceptability scores for
all five questions
[108]
ODTs vs oral solution Desloratadine 0–12 years Parents Questionnaire ‘Preference’ measured using
likelihood of trying ODT and
relative preference to current
medicines
65% of parents in Spain
preferred the ODTs compared to
55% in Italy, 48% in France and
26% in The Netherlands
[109]
Sprinkles vs syrup Valproate 5–16 years Parents and
children
Questionnaire ‘Preference’, direct comparison
of the formulations
Nine out of 12 parents preferred
sprinkles over syrup; similarly
nine out of 12 children preferred
sprinkles over syrup
[40]
Sprinkles vs oral drops Iron supplement 5–7 months Parents Questionnaire ‘Ease of administration’, not
defined
Parents were significantly more
likely to be concerned about
using sprinkles as a new product
(12% vs 0%) and about safety of
sprinkles for infants (14% vs
1.3%) than oral drops; parents in
the oral drop group were more
likely to report difficulty in
integrating administration of
the supplement to daily routine
than (38% vs 17%)
[43]
Sprinkles vs oral drops Iron supplement 8–20 months Parents Questionnaire ‘Ease of use’, not defined 92.9% of children expressed
dislike of the oral drops and
6.5% objected to take the
sprinkles
[53]
Granules vs capsules Pancreatic
enzyme
replacement
6–36 months Parents Questionnaire ‘Preference’ 51% parents preferred the
granules and 23% preferred the
capsules
[55]
Dispersible tablets vs
capsules
Levodopa/
benserazide
Parkinson’s disease
patients, mean age
79.5 years
Patients Not defined Not defined Of eight participants, two
patients preferred the
dispersible tablet, three had no
preference and three preferred
capsules for reason of
convenience
[33]
Modified release granules vs
oral solution
Valproate 6.7 3.6 years
(acceptability in
children was
assessed in those
older than 4 years)
Children
and parents
Questionnaire with five-point facial
hedonic scale
‘Palatability’, defined as taste of
the medicine; ‘ease of
administration’, defined as no
problem in giving the medicine
to the child
The overall palatability score of
granules was significantly
higher than the solution in
children and parents; parents
reported significantly fewer
problems in giving the granules
to their children than the
solution
[52]
Creon110 000 microspheres
(0.7–1.6 mm in a 50% smaller
capsule) vs Creon18000
microspheres (1.0–2.0 mm)
Pancreatic
enzyme
replacement
3–17 years Children Questionnaire ‘Preference’, with reference to
ease of swallowing, presence of
an aftertaste and feeling of
fullness after taking the
medicine
87% preference for Creon1 10
000 over 7.4% preference for
Creon1 8000
[110]
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Syrup vs suspensions vs oral
solutions
Antibiotics 0.5 months to 14
years (median age 2
years)
Parents or
children if
old enough
to
understand
Questionnaire using five-point facial
scale
‘Acceptability’, defined using
completion of treatment, taste,
spitting out of product and
acceptance to use in the future
A higher favourite was
expressed towards amoxicillin–
clavulanic-acid princeps over
generics. 22.45% children spat
out at least one dose of
antibiotic
[76]
Oral drop vs oral filmstrip Vitamin D 1.9–4.3 weeks Infants and
parents
Observation in infants and
questionnaire for parents using a 1–
10 Likert scale
‘Acceptability’, ‘acceptance’ and
‘preference’ were all used. Infant
acceptance was assessed using
reactions to the administration
An overall preference of 85.4%
was observed for the filmstrips;
however, it was not clear how
this was calculated
[89]
Oral liquid, small tablet
(5 mm in diameter), medium
tablet (10 mm in diameter)
and large gelatin capsule
(22 mm  7 mm)
Placebo 3–17 years Children Observation, using the Pediatric
Oral Medication Screener (POMS)
Ability to swallow oral
medications, with set criteria for
different age groups
(swallowing liquid for 3–5 years,
liquid and small/medium tablets
for 6–10 years and all
formulations for 11–17 years)
28 out of 34 children passed
their age-specific swallowing
criteria. Of the six children who
did not pass the criteria, three
improved pill swallowing ability
after intervention
[65]
Oral solid formulations Placebo 6–11 years and 12–17
years
Children
and
caregivers
Questionnaire ‘Acceptability’, defined as
‘ability’ and ‘willingness’ to take
the formulation
Favourable attitudes towards
tablets and capsules increased
with age until around 14 years.
Chewable and orodispersible
tablets were seen to be
preferable across ages, whereas
multi-particulates were less
favourable
[111]
Oral solid formulations Placebo Over 65 years Patients Questionnaire using 0–10 scoring,
with 10 being the most acceptable
‘Acceptance’ Dispersible/effervescent tablets
and orally disintegrating tablets
were considered to be the most
acceptable, followed by mini-
tablets. Chewable tablets and
granules were the least favoured
[4]
Tablets vs metered dose
inhaler
Zafirlukast tablets
and inhaled
beclomethasone
dipropionate
12–17 years Children Questionnaire ‘Preference’ and ‘ease of use’
which is not defined
70% children preferred the
tablets compared with 27%
preferred the inhaler; 71%
preferred the tablets for ease of
use compared with 29%
preferred the inhaler for ease of
use
[112]
Chewable tablets vs
metered-dose inhaler
Montelukast
sodium tablets
and inhaled
cromolyn sodium
6–11 years Parents and
children
Questionnaire using six-point rating
scale
‘Preference’ and ‘satisfaction’.
Satisfaction was assessed using
seven questions including
overall satisfaction on treatment
outcome and medication used,
convenience and difficulty in
administration, interference
with life style and taken as
instructed
Significantly more parents and
children preferred the oral
formulation compared with the
inhaler (87% vs 12% and 82% vs
17%, respectively). Parents and
children expressed greater
overall satisfaction with the oral
formulation than with the
inhaler
[113]
Oral formulations (tablets or
syrup) vs inhaler
Asthmatic drugs 0–5, 6–10,11–15, 16–
30 and 31–60 years
Patients and
parents for
children
under 5
years old
Questionnaire ‘Preference’ 55–65% children below 15 years
old preferred oral formulations
over inhaler. There was a
significant trend favouring
inhaler with increasing age
[114]
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Tablets vs transdermal
patches
Methylphenidate Median age 12,
ranging 5–17
Parents/
carers
Online survey ‘Preference’ 59.5% parents preferred for their
child to take one tablet per day
compared with 33.0% preferred
transdermal patches and 12.5%
preferred three tablets taken per
day
[115]
Oral formulations vs
transdermal patches
Anti-Alzheimer’s
disease drugs
Mean age 77 years Caregivers Questionnaire ‘Preference’ For patients who were exposed
to oral and transdermal
treatments, caregivers showed
higher preference for
transdermal patches (82.4%)
compared with oral therapy
(17.6%); for patients only treated
with one therapy, caregivers
preferred the treatment to
which the patient was exposed
[116]
Oral formulations vs
transdermal patches
Anti-Alzheimer’s
disease drugs
Mean age 77 years Caregivers Questionnaire using 0–10 rating
scale
‘Satisfaction’, ease of
administration, global
compliance, satisfaction relative
to treatment received
Satisfaction was significantly
higher for transdermal patches
compared with oral
medications; over 60% of
caregivers of patients treated
with patches reported a score
between 9 and 10 compared to
46% of caregivers of patients on
oral medications
[82]
Oral formulations vs
transdermal patches
Rotigotine 74.6  8.3 (patients
with Parkinson’s
disease)
Caregivers
and
physicians
Questionnaire using five-point
rating scale
‘Advantageous’, comparison of
advantages of transdermal
patches with oral formulations
Caregivers and physicians caring
for patients with Parkinson’s
disease rated the transdermal
patch to be more advantageous
compared with oral
formulations
[83]
Oral liquid vs rectal
formulations
Acetaminophen 6 months to 6 years Parents A single 10 cm VAS ‘Satisfaction’, not defined There was no significant
difference in parental
satisfaction between oral and
rectal routes of administration
[49]
a ODT: orally disintegrating tablets.
b VAS: Visual Analogue Scale.
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TABLE 5
Summary of methodology directly related to acceptability
assessments
Number of
studies
% of studies
(total n = 68)
Formulation type evaluated
Tablet (including mini-tablet) 30 44
Capsule 13 19
Sprinkle/powder/sachet/granule/microspheres 9 13
Oral solution/drop/liquid not defined 8 12
Syrup 8 12
Oral formulation vs other delivery routes
(transdermal patches/inhaler)
8 12
ODTa 7 10
Oral formulation in general 6 9
Suspension 5 9
Dispersible/effervescent tablet 5 7
Chewable tablet 2 3
Oral film strip 1 1
Candy as mock formulation 1 1
Methodology directly related to acceptability
assessment
Questionnaire/survey 41 60
Observation 16 24
Interview 4 6
Scintigraphy/videoendoscopy 4 6
Other (diary entrance/not defined) 2 3
Acceptability synonym used
‘Acceptability’ 17 25
‘Ability/capability to swallow’/’success
in swallowing’/’oesophageal transit’/’
penetration aspiration score’
17 25
‘Preference’ 13 19
‘Convenience/ease/problems of
administration/use’
6 9
‘Acceptance’ 4 6
‘Palatability’ 3 4
‘Satisfaction’ 2 3
‘Tolerance’ 1 1
‘Medication taking difficulty score’ 1 1
‘Opinion’ 1 1
‘Advantageous’ 1 1
aODT: orally disintegrating tablets.
TABLE 6
Study design considerations for acceptability assessments of
pharmaceutical dosage forms in children and older adults
Study types Clinical trials (randomisation, open/blind, single/multi-
centred) vs other types of studies (e.g., standalone
acceptability investigation, post-marketing survey)
Study settings Hospital vs special clinics vs community e.g., home,
school, children centre for children or home,
nursing home, residential home, health centre
for older adults
Population
characteristics
- Age (division into subgroups according to age)
- Health volunteers vs children
or older adults patients with diseases (disease status)
- Developmental disabilities for children-
- Co-morbidity for older adults
- Swallowing difficulties
Age-related impairments (e.g., visual/cognitive
impairments) for older adults
- Past experiences in taking medicines
- Current medications
and whether or not polypharmacy for older adults
Study methods
and tools
- Interviews/focus groups/questionnaires/
observations/diary entries
- Facial scale/Likert scale/visual analogue scale
Details in
methodology
- Number of participants
- Study duration (short vs long term use)
- Number of administration attempts
- Person who answers the question e.g.,
children vs parents/carers/healthcare
professionals for children
or e.g., patients vs partners/carers/healthcare
professionals for older adults
- Carers experiences when giving/administering
medicines
Dosage forms
to be studied
- Acceptability of a single dosage form or
comparison between more than one
- Placebo vs drug-containing medicines
- Number of dosage forms to be taken at the same time
- Administration as labelled or unlicensed use
Acceptability
definition
Standardised terms/definitions to be used vs
a variety of terms needed
Acceptability
criteria
Universally agreed acceptability standard
(e.g., 70%) vs case by case basis
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are questionable but their validity improves between 8–11 years of
age. This taskforce considered that self-reports should be preferred
only for children older than 11 years. In addition, the ASTM
‘Standard Guide for Sensory Evaluation of Products by Children’,
although developed for food products, provides guidance on the
development of studies in children of different ages [85]. The EMA
has also expressed a view that it is preferable for acceptability
studies to be conducted in the most relevant patient population as
an integrated part of clinical trials [24,26].
Acceptability definitions and criteria
Although attempts were made to evaluate acceptability of dosage
forms in the two patient populations, a common definition of
acceptability was not applied in the studies. In several studies,
terms such as ‘acceptability’, ‘ease of administration’, ‘ease of use’,844 www.drugdiscoverytoday.com‘preference’, ‘ability in swallowing’, ‘ease of swallowing’,
‘problems in administering tablet’ and ‘success in swallowing pills’
were used as the evaluation for the success or otherwise of the
study without clear definition of these terms (Table 6).
‘Acceptability’ has been defined in recent guidelines [24,25],
which has been a key step forward in improving the understanding
in acceptability testing as researchers start designing their studies
to explore the ability and willingness of the patients to take their
medicine as intended. In other words, the definition enables
researchers to identify and focus to achieve the same aim. Recent
reviews have proposed specific definitions of the terms relevant to
acceptability such as preference and usability [29]. However, it
needs to be noted that these terms differ from the regulatory
definitions of ‘acceptability’. For example, ‘preference’ is not used
as a part of the terminology in regulatory guidelines. Patient
preference of one medicine over another gives only the relative
comparison and not the actual acceptability of the medicine.
Overall acceptability is the combined effect of several contributing
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administration [26]. Consequently, the definition of acceptability
is open to interpretation and the way it is translated into practice
might differ between studies (i.e., different outcome measures and
data collection tools). There is a need for a stream of work to
harmonise the study design as well as the collection and analysis of
data to be able to compare the outcomes of different studies.
A first attempt to consider simultaneously the contributing
factors of acceptability has been described recently [86], whereby
acceptability has been approached as a multidimensional concept.
An acceptability reference framework, map and profiles have been
designed using evaluations of medicine use in real-life conditions.
For each evaluation, a set of contributing factors has been observed
and the data have been treated with multiple correspondence
analysis to define an acceptability map. Utilising a clustering
process, evaluations reflecting treatments positively accepted
emerged in a different cluster than those that were negatively
accepted. The first results showed that in 70% of the treatment
evaluations performed the medicines were positively accepted
(234 children, 109 medicines) [86]. A further larger scale applica-
tion of the tool showed similar results with 72% positive accept-
ability in 850 children and 80% positive acceptability in 950 older
patients (unpublished data from F.R.). The reliability of the model
has been validated in a paediatric population [87].
Other tools might be considered in adaptation for acceptability
assessment, such as the Medication Acceptance Scale (MAS) which
evaluates a child’s reaction to medication based on facial expres-
sions, reactions upon ingestion and amount of dose swallowed
[88]. This tool could be useful for patients with difficulties using
scales (e.g., young children, older patients with certain diseases).
However, it needs to be noted that the MAS has been specifically
designed for infants and certain items (e.g., crying and body
movement or level of agitation) might not be suitable for other
populations such as older patients. In the studies analysed in this
review, Rodd et al. modified the MAS by deleting the section
regarding gross motor movements and the authors stated that
‘‘it was not deemed appropriate for newborns” [89]. Other tools
used in PRO measures include the Treatment Satisfaction Ques-
tionnaire for Medication (TSQM) [90], Treatment Satisfaction with
Medicines Questionnaire (SATMED-Q) [91] and ACCEPT [92] and
those recommended by the Equator Network (http://www.
equator-network.org/reporting-guidelines/), which could be con-
sidered for adaptation in acceptability assessment. However, these
PRO instruments are proposed to assess ‘satisfaction’, which
includes other factors of interest (e.g., side effects, symptom relief
and effectiveness) other than acceptability of the formulation.
Moreover, these tools have been validated in adult populationsand their appropriateness for use in children (especially aged
under 12 years) and older patients needs to be carefully evaluated.
Correspondingly, the criteria used for determining whether or not
a formulation is acceptable is missing from the studies. Again, a
universally agreed arbitrary limit or standard (e.g., 70% or 80%
acceptance) might be considered; however, in certain circum-
stances a risk:benefit-based approach might be more appropriate
on a case-by-case basis. One solution would be to join the efforts of
key stakeholders to prepare a reporting guideline for medicine
acceptability testing as for other main study types such as obser-
vational studies and randomised trials. The standardisation of
study methodology and data reporting will assist researchers to
publish high-impact health research and generate evidence-based
information towards better medicines for children and older peo-
ple. It is to be acknowledged that scientific publications could be
used as supportive evidence in the approval of new medicines,
although regulatory bodies might still require the original data to
be submitted and reviewed as part of regulatory procedures.
Limitations of the study
This review has focused only on formulation aspects of the phar-
maceutical product design and does not include other aspects such
as packaging or device used. It should be acknowledged that
aspects of a medicinal product other than formulation also have
profound impacts on patient acceptability, as shown by Drumond
et al. [29]. Data extraction did not consider the effects of the study
settings, such as the presence of caregivers or the researcher or
observer on the outcome measures on acceptability. However, this
might change the behaviour of the child or older patient and alter
the overall acceptability results.
Concluding remarks
The development of medicines that are appropriate and acceptable
to paediatric and older patients is of paramount importance in
ensuring adherence and medication safety [93]. However, asses-
sing the acceptability of medicines in these patient groups is
challenging, considering the complexity of the study population
and the diversity of the end goal of the individual investigation.
Published methods reporting acceptability of oral medicines in
children and older adults show a lack of standardisation in terms of
participant characteristics, the study settings, evaluation tools and
endpoint criteria. A consensus agreement between academia, the
pharmaceutical industry and regulators would be welcomed to
harmonise and standardise the methodology for acceptability
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